Liver Cancer Therapeutics Market to Cross USD11 billion by 2025
Increasing prevalence of liver cancer and introduction of new
targeted therapies to drive global liver cancer therapeutics market through 2025.
According to
TechSci Research report, “Global Liver
Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age,
By Factors, By Route of Administration, By Distribution Channel, By Region,
Competition, Forecast & Opportunities, 2025”, the global liver cancer therapeutics market is projected to
surpass USD11 billion by 2025 owing to factors like increasing prevalence of
liver cancer, rising alcohol consumption, and development
of novel innovative therapeutic drugs. Liver cancer accounts for the fourth
foremost reason for deaths associated with cancer around the world. Unhealthy lifestyle
such as excessive consumption of alcohol, frequent smoking, poor eating habits
are some of the factors that increase the risk factors contributing to liver
cancer. Apart from this, increase in incidences of
HBV/HCV coinfection and cirrhosis are other common factors contributing to the
rise in number of liver cancer cases across the world. Scientists around the world are working on research
and development activities for creating novel treatments for liver cancer,
which is expected to drive the market for liver cancer therapeutics over the
next five years.
The liver cancer therapeutic market offers tremendous
opportunities to develop breakthrough targeted therapies to meet the emerging
needs of a large target population. Innovative treatment approaches, strong
clinical pipeline therapeutic drugs, and combination regimes such as checkpoint
inhibitors are anticipated to change the liver cancer therapeutic market in the
coming years. However, high capital investment, stringent drug approval
process, high research & development cost and adverse side-effects of
cancer treatment medications are factors which might hinder the growth of liver
cancer therapeutics market.
Browse 206 market data Figures spread through 191 Pages and an in-depth TOC on "Global Liver Cancer Therapeutics Market"
https://www.techsciresearch.com/report/liver-cancer-therapeutics-market/4667.html
The global liver
cancer therapeutics market is segmented based on cancer type, therapy,
equipment, age, factors, route of administration, distribution channel and region.
Based on cancer type, the market is segmented into hepatocellular carcinoma,
cholangiocarcinoma, hepatoblastoma, angiosarcoma and liver metastasis. The
hepatocellular carcinoma segment accounted for the largest market share in 2019
owing to its high prevalence, especially in Asian and African nations. Based on
therapy, the market is segmented into chemotherapy and radiation therapy, immunotherapy, targeted
therapy, and others. Among them, the chemotherapy & radiation therapy
segment is anticipated to be the largest segment through 2025. Based on the equipment,
computed radiography is expected to dominate the global liver cancer market
share as it possesses improved imaging capability, particularly in terms of
spatial resolution and small detail detectability. Based on distribution channel,
hospital pharmacies are anticipated to hold the largest market share of 55.83%
by 2025 due to immediate accessibility of liver therapeutic drugs. In terms of
region, North America holds the largest market share and is expected to
continue dominance during the forecast period owing to high prevalence of liver
cancer, high levels of awareness about the disease, availability of cancer
therapeutic drugs, and well-established health care infrastructure in the
region. Additionally, large base of pharmaceutical and biotechnology companies
and rising adoption of technologically advanced diagnostic tools to enhance the
global liver cancer therapeutic market during the forecast period.
Major players operating in
the global liver cancer therapeutics market include Bayer
AG, Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Bristol-Myers Squibb
Company, Eisai Co., Ltd., Pfizer Inc., Exelixis, Inc., Merck, Celsion
Corporation, Johnson & Johnson, Novartis International AG, Sanofi S.A., Eli
Lilly and Company, Perkin Elmer, Sun Pharmaceutical Industries Ltd., AbbVie
Inc., Amgen Inc., AstraZeneca, Philips Healthcare Pvt. Ltd and others. The
market players are focusing on research and development activities to bring
innovative treatments for fighting liver cancer. Moreover, government funding in
various countries is also encouraging R&D activities, which is positively
influencing the market across the globe.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4667
Customers can also request for 10% free
customization on this report.
“Aging population, rising
alcohol consumption and growing cases of HBV/HCV coinfection and cirrhosis are driving the global
liver cancer therapeutics market. Nowadays, a variety of
treatment options are available for liver cancer patients. However, increasing
prevalence of different types of liver cancer demands even more effective and innovative
drugs and treatment options. The stakeholders need to invest more in R&D
activities for further expansion of their respective market shares and build a
strong foothold, globally.,” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based global management consulting firm.
“Global Liver Cancer Therapeutics Market By Cancer
Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration,
By Distribution Channel, By Region, Competition, Forecast & Opportunities,
2025” has evaluated
the future growth potential of liver cancer therapeutics market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges and opportunities in global liver cancer therapeutics market.
Browse
Related Reports
Europe Biosimilar
Insulin Glargine & Lispro Market By End User (Type 1 Diabetes and Type 2
Diabetes), By Country (Germany, United Kingdom, France, Italy, Spain, Russia,
Turkey, Poland, The Netherlands, Austria & Rest of Europe), Competition,
Forecast & Opportunities, 2024
https://www.techsciresearch.com/report/europe-biosimilar-insulin-glargine-and-lispro-market/4278.html
Global
Contact Lenses Market By Product Type (Soft Contact Lenses, Gas Permeable
Contact Lenses & Others), By Design (Spherical, Toric & Others), By
Wear Type (Disposable & Reusable), By Distribution Channel (Store-based
& Non-based Based), By Region, Competition, Forecast & Opportunities,
2024
https://www.techsciresearch.com/report/contact-lenses-market/4132.html
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]